Technology stocks were rising premarket Thursday, with the Technology Select Sector SPDR Fund gaining 0.4% while the SPDR S&P Semiconductor ETF was flat.
Simulations Plus surged past 10% after.
Simulations Plus said Thursday that the US Food and Drug Administration has renewed its licenses to the DILIsym software platform.
Financial details weren t disclosed.
The one-year renewal will.
Simulations Plus, Inc. announced that the U.S. FDA has renewed its licenses to the DILIsym software platform. DILIsym is the industry gold standard for quantitative systems toxicology software.
Shares of Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) gapped up before the market opened on Thursday following a better than expected earnings announcement. The stock had previously closed at $38.46, but opened at $44.91. Simulations Plus shares last traded at $46.28, with a volume of 95,888 shares changing hands. The technology company reported […]
Companies Reporting Before The Bell • Acuity Brands (NYSE:AYI) is projected to report quarterly earnings at $3.25 per share on revenue of $907.75 million.